Accessing the specific capacity of TIL-derived CD8 T-cells to suppress tumor recurrence in resectable HBV-HCC patients
Janine Kah, Lisa Staffeldt, Gregor Mattert, Tassilo Volz, Kornelius Schulze, Asmus Heumann, Maximillian Voß, Marie-Charlotte Hoell, Meike Goebel, Sven Peine, Maura Dandri, Stefan Lüth
This study evaluates the effectiveness of TIL-derived CD8 T-cells in suppressing tumor recurrence in HBV-HCC patients through adoptive cell transfer and immune checkpoint inhibitor combination.
bioRxiv · Dec 5, 2024 · PreprintImmunology